Hedner U
Novo Nordisk A/S, Research and Development, Maaloev, Denmark.
Semin Hematol. 2001 Oct;38(4 Suppl 12):43-7. doi: 10.1016/s0037-1963(01)90147-7.
Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Denmark) induces hemostasis in life- and limb-threatening bleeds and in major surgery of hemophilia A and B patients, regardless of inhibitor titer. A total of more than 6,500 patients have been treated, and NovoSeven has been administered in more than 180,000 standard doses. Experience gained from these clinical situations suggests that NovoSeven should be administered as a 90- to 110-microg/kg bolus dose every second hour. Hemophilia patients with mild to moderate bleeding episodes require two to three doses to achieve complete hemostasis, whereas patients with severe bleeding episodes may require more doses. For major surgery and in cases of life-threatening bleeding, dosing every second hour for the first 24 hours may be required. Thereafter, the same dose, but with longer intervals between doses, is recommended. Recent in vitro experiments indicate that even higher doses of NovoSeven may be needed to achieve full thrombin generation in the absence of factor VIII (FVIII), factor IX (FIX), and factor XI (FXI).
重组活化凝血因子VII（rFVIIa；诺其，丹麦诺和诺德公司）可诱导止血，用于危及生命和肢体的出血以及甲型和乙型血友病患者的大手术，无论其抑制剂滴度如何。共有超过6500名患者接受了治疗，且诺其的给药剂量已超过180000标准剂量。从这些临床情况中获得的经验表明，诺其应以每两小时90至110微克/千克的推注剂量给药。轻度至中度出血发作的血友病患者需要两至三剂才能实现完全止血，而严重出血发作的患者可能需要更多剂量。对于大手术和危及生命的出血情况，可能需要在最初24小时内每两小时给药一次。此后，建议使用相同剂量，但给药间隔时间更长。最近的体外实验表明，在缺乏凝血因子VIII（FVIII）、凝血因子IX（FIX）和凝血因子XI（FXI）的情况下，可能需要更高剂量的诺其才能实现完全的凝血酶生成。
